黄芪建中汤加减联合艾灸治疗脾胃虚寒型慢性萎缩性胃炎OA

Objective:To observe the clinical efficacy of Modified Astragalus Center-Fortifying Decoction combined with moxibustion on chronic atrophic gastritis(CAG)with spleen-stomach deficiency-cold syndrome.Methods:A total of 80 patients with CAG of spleen-stomach deficiency-cold syndrome,admitted to Henan Integrative Medicine Hospital from December 2022 to December 2023,were se-lected as the study subjects,and then divided into the control group and the observation group according to the random number table method,with 40 cases in each group.The control group was treated with Rebamipide Capsules,with Omeprazole Enteric-coated Capsules added for those with significant acid reflux and heartburn.The observation group received Modified Astragalus Center-Fortifying Decoc-tion combined with moxibustion in addition to the treatment given to the control group.The clinical efficacy,and changes in gastroscopic pathological scores,levels of inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),hypersensitive C-reactive protein(hs-CRP)],and gastric mucosal histological indicators[epidermal growth factor(EGF)and nitric oxide(NO)]before and af-ter treatment were compared between the two groups.Results:After treatment,gastroscopic pathological scores for chronic inflammation,glandular atrophy,and intestinal metaplasia in the two groups were all lower than those before treatment within the same group,and the scores in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).The ef-fective rate in the observation group was 92.50％,higher than 77.50％in the control group,with a statistically significant difference(P<0.05).After treatment,the levels of inflammatory factors(TNF-α,IL-6,hs-CRP)in the two groups were all lower than those be-fore treatment within the same group,and the above levels in the observation group were lower than those in the control group,with sta-tistically significant differences(P<0.05).The effective rate in the observation group was 97.50％,higher than 77.50％in the con-trol group,with a statistically significant difference(P<0.05).After treatment,the levels of EGF and NO in the two groups were higher than those before treatment within the same group,and the above levels in the observation group were higher than those in the control group,with statistically significant differences(P<0.05).The incidence of adverse reactions in the observation group was 5.00％,low-er than 17.50％in the control group,with a statistically significant difference(P<0.05).Conclusion:Modified Astragalus Center-For-tifying Decoction combined with moxibustion for CAG with spleen-stomach deficiency-cold syndrome can significantly improve gastroin-testinal symptoms,reduce the levels of inflammatory factors,and enhance the clinical efficacy.